55 related articles for article (PubMed ID: 12162717)
1. Selective and sustained occupancy of prostatic alpha1-adrenoceptors by oral administration of KMD-3213 and its plasma concentration in rats.
Okura T; Yamada S; Abe Y; Kimura R
J Pharm Pharmacol; 2002 Jul; 54(7):975-82. PubMed ID: 12162717
[TBL] [Abstract][Full Text] [Related]
2. Ex vivo occupancy by tamsulosin of alpha1-adrenoceptors in rat tissues in relation to the plasma concentration.
Ohkura T; Yamada S; Deguchi Y; Kimura R; Matsushima H; Higuchi S; Inagaki O; Honda K; Takenaka T
Life Sci; 1998; 63(24):2147-55. PubMed ID: 9851306
[TBL] [Abstract][Full Text] [Related]
3. In vivo demonstration of alpha(1A)-adrenoceptor subtype selectivity of KMD-3213 in rat tissues.
Yamada S; Okura T; Kimura R
J Pharmacol Exp Ther; 2001 Jan; 296(1):160-7. PubMed ID: 11123376
[TBL] [Abstract][Full Text] [Related]
4. In vivo receptor binding of novel alpha1-adrenoceptor antagonists for treatment of benign prostatic hyperplasia.
Yamada S; Ohkura T; Kimura R; Kawabe K
Life Sci; 1998; 62(17-18):1585-9. PubMed ID: 9585140
[TBL] [Abstract][Full Text] [Related]
5. Ex vivo and in vivo alpha1-adrenoceptor binding characteristics of a novel alpha1L-adrenoceptor antagonist, JTH-601, in rat tissues.
Ohkura T; Yamada S; Tohma A; Kimura R; Aisaka K
Biol Pharm Bull; 1999 Jul; 22(7):687-90. PubMed ID: 10443463
[TBL] [Abstract][Full Text] [Related]
6. In vivo measurement by [3H]Tamsulosin of alpha1 adrenoceptors in rat tissues in relation to the pharmacokinetics.
Yamada S; Ohkura T; Deguchi Y; Kimura R
J Pharmacol Exp Ther; 1999 Jun; 289(3):1575-83. PubMed ID: 10336555
[TBL] [Abstract][Full Text] [Related]
7. KMD-3213, a uroselective and long-acting alpha(1a)-adrenoceptor antagonist, tested in a novel rat model.
Akiyama K; Hora M; Tatemichi S; Masuda N; Nakamura S; Yamagishi R; Kitazawa M
J Pharmacol Exp Ther; 1999 Oct; 291(1):81-91. PubMed ID: 10490890
[TBL] [Abstract][Full Text] [Related]
8. Prediction of alpha1-adrenoceptor occupancy in the human prostate from plasma concentrations of silodosin, tamsulosin and terazosin to treat urinary obstruction in benign prostatic hyperplasia.
Yamada S; Kato Y; Okura T; Kagawa Y; Kawabe K
Biol Pharm Bull; 2007 Jul; 30(7):1237-41. PubMed ID: 17603160
[TBL] [Abstract][Full Text] [Related]
9. Disposition and alpha(1)-adrenoceptor binding characteristics of JTH-601 and its metabolites in rat tissues.
Yamada S; Okura T; Kimura R; Deguchi Y; Suzuki Y; Kobayashi T; Aisaka K
Drug Metab Dispos; 2000 Dec; 28(12):1487-92. PubMed ID: 11095588
[TBL] [Abstract][Full Text] [Related]
10. A selective alpha1A-adrenoceptor antagonist inhibits detrusor overactivity in a rat model of benign prostatic hyperplasia.
Tatemichi S; Akiyama K; Kobayashi M; Yamazaki Y; Yokoyama O; Uruno T
J Urol; 2006 Sep; 176(3):1236-41. PubMed ID: 16890732
[TBL] [Abstract][Full Text] [Related]
11. Uroselectivity in male dogs of silodosin (KMD-3213), a novel drug for the obstructive component of benign prostatic hyperplasia.
Tatemichi S; Tomiyama Y; Maruyama I; Kobayashi S; Kobayashi K; Maezawa A; Kobayashi M; Yamazaki Y; Shibata N
Neurourol Urodyn; 2006; 25(7):792-9; discussion 800-1. PubMed ID: 16894620
[TBL] [Abstract][Full Text] [Related]
12. Up-regulation of α1a and α1d-adrenoceptors in the prostate by administration of subtype selective α1-adrenoceptor antagonist tamsulosin in patients with benign prostatic hyperplasia.
Kojima Y; Sasaki S; Kubota Y; Imura M; Oda N; Kiniwa M; Hayashi Y; Kohri K
J Urol; 2011 Oct; 186(4):1530-6. PubMed ID: 21855934
[TBL] [Abstract][Full Text] [Related]
13. Relationship between prostatic alpha(1)-adrenoceptor binding and reduction in intraurethral pressure following continuous infusion of KMD-3213 in rats.
Akiyama K; Tatemichi S; Katayama S; Nakajima M; Oki T; Okura T; Yamada S; Kimura R
Pharmacology; 2002; 64(3):140-7. PubMed ID: 11834890
[TBL] [Abstract][Full Text] [Related]
14. Z-350, a novel compound with alpha 1-adrenoceptor antagonistic and steroid 5 alpha-reductase inhibitory actions: pharmacological properties in vivo.
Fukuta Y; Fukuda Y; Higashino R; Yoshida K; Ogishima M; Tamaki H; Takei M
J Pharmacol Exp Ther; 1999 Sep; 290(3):1013-8. PubMed ID: 10454472
[TBL] [Abstract][Full Text] [Related]
15. Role of supraspinal alpha1-adrenoceptors for voiding in conscious rats with and without bladder outlet obstruction.
Gu BJ; Ishizuka O; Igawa Y; Nishizawa O; Andersson KE
J Urol; 2002 Apr; 167(4):1887-91. PubMed ID: 11912454
[TBL] [Abstract][Full Text] [Related]
16. Alpha-1 adrenoceptor up-regulation induced by prazosin but not KMD-3213 or reserpine in rats.
Zhang L; Taniguchi T; Tanaka T; Shinozuka K; Kunitomo M; Nishiyama M; Kamata K; Muramatsu I
Br J Pharmacol; 2002 Apr; 135(7):1757-64. PubMed ID: 11934817
[TBL] [Abstract][Full Text] [Related]
17. Characterization of muscarinic receptor binding and inhibition of salivation after oral administration of tolterodine in mice.
Oki T; Maruyama S; Takagi Y; Yamamura HI; Yamada S
Eur J Pharmacol; 2006 Jan; 529(1-3):157-63. PubMed ID: 16316647
[TBL] [Abstract][Full Text] [Related]
18. History and nomenclature of alpha1-adrenoceptors.
Langer SZ
Eur Urol; 1999; 36 Suppl 1():2-6. PubMed ID: 10438241
[TBL] [Abstract][Full Text] [Related]
19. Effects of KMD-3213, a uroselective alpha 1A-adrenoceptor antagonist, on the tilt-induced blood pressure response in normotensive rats.
Akiyama K; Hora M; Yamagishi R; Kitazawa M
Jpn J Pharmacol; 2002 Oct; 90(2):131-7. PubMed ID: 12419883
[TBL] [Abstract][Full Text] [Related]
20. Actions of A-131701, a novel, selective antagonist for alpha-1A compared with alpha-1B adrenoceptors on intraurethral and blood pressure responses in conscious dogs and a pharmacodynamic assessment of in vivo prostatic selectivity.
Hancock AA; Brune ME; Witte DG; Marsh KC; Katwala S; Milicic I; Ireland LM; Crowell D; Meyer MD; Kerwin JF
J Pharmacol Exp Ther; 1998 May; 285(2):628-42. PubMed ID: 9580607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
